Biogen Net Current Asset Value from 2010 to 2026

BIIB Stock  USD 185.45  8.69  4.92%   
Biogen's Net Current Asset Value is steady over the years with stable fluctuation. Net Current Asset Value is expected to dwindle to 0.00. At present, Biogen's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 302.2 M, whereas Operating Income is forecasted to decline to about 1.6 B. . View All Fundamentals
 
Net Current Asset Value  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
0.0
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Biogen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biogen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 812.9 M, Interest Expense of 302.2 M or Selling General Administrative of 2.8 B, as well as many indicators such as Price To Sales Ratio of 2.52, Dividend Yield of 0.0028 or PTB Ratio of 1.46. Biogen financial statements analysis is a perfect complement when working with Biogen Valuation or Volatility modules.
  
Build AI portfolio with Biogen Stock
Check out the analysis of Biogen Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out the analysis of Biogen Correlation against competitors.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. Projected growth potential of Biogen fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biogen assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.192
Earnings Share
10.98
Revenue Per Share
68.815
Quarterly Revenue Growth
0.028
Return On Assets
0.0575
Biogen Inc's market price often diverges from its book value, the accounting figure shown on Biogen's balance sheet. Smart investors calculate Biogen's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Biogen's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Biogen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biogen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.